Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Alhalabi O, et al. Eur Urol Oncol. 2023 Dec;6(6):611-620. doi: 10.1016/j.euo.2023.09.004. Epub 2023 Oct 11. Eur Urol Oncol. 2023. PMID: 37833193
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.
Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Alhalabi O, et al. Among authors: wilson nr. BJUI Compass. 2021 Oct 11;3(1):37-44. doi: 10.1002/bco2.113. eCollection 2022 Jan. BJUI Compass. 2021. PMID: 35475152 Free PMC article.
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Alhalabi O, et al. Among authors: wilson nr. Int J Cancer. 2021 Jul 15;149(2):387-393. doi: 10.1002/ijc.33560. Epub 2021 Mar 24. Int J Cancer. 2021. PMID: 33739450
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Alhalabi O, et al. Clin Genitourin Cancer. 2022 Feb;20(1):e16-e24. doi: 10.1016/j.clgc.2021.07.004. Epub 2021 Jul 12. Clin Genitourin Cancer. 2022. PMID: 34362693
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis.
Soto-Lanza F, Glick L, Chan C, Zhong L, Wilson N, Faiz S, Gandhi S, Naing A, Heymach JV, Shannon VR, Franco-Vega M, Liao Z, Lin SH, Palaskas NL, Wu J, Shroff GS, Altan M, Sheshadri A. Soto-Lanza F, et al. Clin Lung Cancer. 2024 Nov;25(7):624-633.e2. doi: 10.1016/j.cllc.2024.07.017. Epub 2024 Aug 3. Clin Lung Cancer. 2024. PMID: 39183094
130 results